134 related articles for article (PubMed ID: 33831696)
1. Discovery of novel pyrimidine molecules containing boronic acid as VCP/p97 Inhibitors.
Zhang Y; Xie X; Wang X; Wen T; Zhao C; Liu H; Zhao B; Zhu Y
Bioorg Med Chem; 2021 May; 38():116114. PubMed ID: 33831696
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a new class of valosine containing protein (VCP/P97) inhibitors for the treatment of non-small cell lung cancer.
Wang X; Bai E; Zhou H; Sha S; Miao H; Qin Y; Liu Z; Wang J; Zhang H; Lei M; Liu J; Hai O; Zhu Y
Bioorg Med Chem; 2019 Feb; 27(3):533-544. PubMed ID: 30606672
[TBL] [Abstract][Full Text] [Related]
3. A covalent p97/VCP ATPase inhibitor can overcome resistance to CB-5083 and NMS-873 in colorectal cancer cells.
Zhang G; Li S; Wang F; Jones AC; Goldberg AFG; Lin B; Virgil S; Stoltz BM; Deshaies RJ; Chou TF
Eur J Med Chem; 2021 Mar; 213():113148. PubMed ID: 33476933
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, in vitro and in vivo evaluation, and structure-activity relationship (SAR) discussion of novel dipeptidyl boronic acid proteasome inhibitors as orally available anti-cancer agents for the treatment of multiple myeloma and mechanism studies.
Lei M; Feng H; Bai E; Zhou H; Wang J; Shi J; Wang X; Hu S; Liu Z; Zhu Y
Bioorg Med Chem; 2018 Aug; 26(14):3975-3981. PubMed ID: 29934218
[TBL] [Abstract][Full Text] [Related]
5. Discovery and optimization of tetrahydropyrido[4,3-d]pyrimidine derivatives as novel ATX and EGFR dual inhibitors.
Jing T; Miao X; Jiang F; Guo M; Xing L; Zhang J; Zuo D; Lei H; Zhai X
Bioorg Med Chem; 2018 May; 26(8):1784-1796. PubMed ID: 29496411
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer.
Lei M; Feng H; Bai E; Zhou H; Wang J; Qin Y; Zhang H; Wang X; Liu Z; Hai O; Liu J; Zhu Y
Org Biomol Chem; 2019 Jan; 17(3):683-691. PubMed ID: 30601533
[TBL] [Abstract][Full Text] [Related]
7. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors.
Wang R; Yu S; Zhao X; Chen Y; Yang B; Wu T; Hao C; Zhao D; Cheng M
Eur J Med Chem; 2020 Feb; 188():112024. PubMed ID: 31923858
[TBL] [Abstract][Full Text] [Related]
9. Novel p97/VCP inhibitor induces endoplasmic reticulum stress and apoptosis in both bortezomib-sensitive and -resistant multiple myeloma cells.
Nishimura N; Radwan MO; Amano M; Endo S; Fujii E; Hayashi H; Ueno S; Ueno N; Tatetsu H; Hata H; Okamoto Y; Otsuka M; Mitsuya H; Matsuoka M; Okuno Y
Cancer Sci; 2019 Oct; 110(10):3275-3287. PubMed ID: 31368616
[TBL] [Abstract][Full Text] [Related]
10. VCP/p97/Cdc48, A Linking of Protein Homeostasis and Cancer Therapy.
Lan B; Chai S; Wang P; Wang K
Curr Mol Med; 2017; 17(9):608-618. PubMed ID: 29521227
[TBL] [Abstract][Full Text] [Related]
11. A structure- and chemical genomics-based approach for repositioning of drugs against VCP/p97 ATPase.
Segura-Cabrera A; Tripathi R; Zhang X; Gui L; Chou TF; Komurov K
Sci Rep; 2017 Mar; 7():44912. PubMed ID: 28322292
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 2-(cyclohexylmethylamino)pyrimidines as a new class of reversible valosine containing protein inhibitors.
Cervi G; Magnaghi P; Asa D; Avanzi N; Badari A; Borghi D; Caruso M; Cirla A; Cozzi L; Felder E; Galvani A; Gasparri F; Lomolino A; Magnuson S; Malgesini B; Motto I; Pasi M; Rizzi S; Salom B; Sorrentino G; Troiani S; Valsasina B; O'Brien T; Isacchi A; Donati D; D'Alessio R
J Med Chem; 2014 Dec; 57(24):10443-54. PubMed ID: 25474526
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and molecular docking study of new monastrol analogues as kinesin spindle protein inhibitors.
El-Hamamsy MH; Sharafeldin NA; El-Moselhy TF; Tawfik HO
Arch Pharm (Weinheim); 2020 Aug; 353(8):e2000060. PubMed ID: 32452567
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and antitumor evaluation of novel 5-methylpyrazolo[1,5-a]pyrimidine derivatives as potential c-Met inhibitors.
Luo G; Ma Y; Liang X; Xie G; Luo Y; Zha D; Wang S; Yu L; Zheng X; Wu W; Zhang C
Bioorg Chem; 2020 Nov; 104():104356. PubMed ID: 33142417
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel tripeptide propylene oxide proteasome inhibitors for the treatment of multiple myeloma.
Zhang W; Wang X; Zhang H; Wen T; Yang L; Miao H; Wang J; Liu H; Yang X; Lei M; Zhu Y
Bioorg Med Chem; 2021 Jun; 40():116182. PubMed ID: 33971487
[TBL] [Abstract][Full Text] [Related]
16. Rational design, molecular docking and synthesis of novel homopiperazine linked imidazo[1,2-a]pyrimidine derivatives as potent cytotoxic and antimicrobial agents.
Mantipally M; Gangireddy MR; Gundla R; Badavath VN; Mandha SR; Maddipati VC
Bioorg Med Chem Lett; 2019 Aug; 29(16):2248-2253. PubMed ID: 31239178
[TBL] [Abstract][Full Text] [Related]
17. Pyrroformyl-containing 2,4-diaminopyrimidine derivatives as a new optimization strategy of ALK inhibitors combating mutations.
Cao M; Chen Y; Zhao T; Wei S; Guo M; Zhai X
Bioorg Med Chem; 2020 Oct; 28(20):115715. PubMed ID: 33069079
[TBL] [Abstract][Full Text] [Related]
18. [1,2,3]Triazolo[4,5-d]pyrimidine derivatives incorporating (thio)urea moiety as a novel scaffold for LSD1 inhibitors.
Li ZH; Ma JL; Liu GZ; Zhang XH; Qin TT; Ren WH; Zhao TQ; Chen XH; Zhang ZQ
Eur J Med Chem; 2020 Feb; 187():111989. PubMed ID: 31881456
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R.
Wang Y; Chen S; Hu G; Wang J; Gou W; Zuo D; Gu Y; Gong P; Zhai X
Eur J Med Chem; 2018 Jan; 143():123-136. PubMed ID: 29174809
[TBL] [Abstract][Full Text] [Related]
20. Allosteric p97 Inhibitors Can Overcome Resistance to ATP-Competitive p97 Inhibitors for Potential Anticancer Therapy.
Wang F; Li S; Gan T; Stott GM; Flint A; Chou TF
ChemMedChem; 2020 Apr; 15(8):685-694. PubMed ID: 32162487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
